Ramalingam, Suresh S.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 552

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 492

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 438

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems

Cancer Genomics and DiagnosticsCancer-related Molecular Pathways

Cited by 431

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Ramalingam, S. S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 366

Scientific Advances in Lung Cancer 2015

Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 284

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

Leighl, N. B., Rekhtman, N., Biermann, W. A., Huang, J., Mino-Kenudson, M., Ramalingam, S. S., West, H., Whitlock, S., & Somerfield, M. R. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 281

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 269

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Papadimitrakopoulou, V. A., Wu, Y.-L., Han, J.-Y., Ahn, M.-J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C.-H., Bulusu, K. C., Laus, G., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 252

An expanded universe of cancer targets

Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 213

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 206

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Owonikoko, T. K., Dahlberg, S. E., Sica, G. L., Wagner, L. I., Wade, J. L., Srkalovic, G., Lash, B. W., Leach, J. W., Leal, T. B., Aggarwal, C., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Research StudiesPARP inhibition in cancer therapy

Cited by 185

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 167

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Dy, G. K., Govindan, R., Velcheti, V., Falchook, G. S., Italiano, A., Wolf, J., Sacher, A. G., Takahashi, T., Ramalingam, S. S., Dooms, C., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 163

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Konduri, K., Gallant, J.-N., Chae, Y. K., Giles, F. J., Gitlitz, B. J., Gowen, K., Ichihara, E., Owonikoko, T. K., Peddareddigari, V., Ramalingam, S. S., et al. (2016) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 144

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 133

LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

Yang, J., Ramalingam, S. S., Jänne, P. A., Cantarini, M., & Mitsudomi, T. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 97

Acetylation regulates ribonucleotide reductase activity and cancer cell growth

Chen, G., Luo, Y., Warncke, K., Sun, Y., Yu, D. S., Fu, H., Behera, M., Ramalingam, S. S., Doetsch, P. W., Duong, D. M., et al. (2019) · Nature Communications

Biochemical and Molecular ResearchDNA Repair Mechanisms

Cited by 82

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., et al. (2022) · Cancer

Cancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy

Cited by 75

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.

Ramalingam, S. S., Ciuleanu, T. E., Pluzanski, A., Lee, J.-S., Schenker, M., Bernabe Caro, R., Lee, K. H., Zurawski, B., Audigier-Valette, C., Provencio, M., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 67

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer

Oxnard, G. R., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Yu, H. A., Saka, H., Horn, L., Goto, K., Ohe, Y., Cantarini, M., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 46

Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors

Ramalingam, S., Fakih, M., Strickler, J., Govindan, R., Li, B. T., Goldberg, S., Gandara, D., Burns, T., Barve, M., Shu, C., et al. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 40

PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis

Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 30

Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.

Li, B. T., Velcheti, V., Price, T. J., Hong, D. S., Fakih, M., Kim, D.-W., Falchook, G. S., Delord, J.-P., Dy, G. K., Ramalingam, S. S., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 27